EBS Technologies has reported the results of a multicentre, 82-patient trial of its Next Wave brain stimulation device for treatment of vision deficits caused by neurological disorders. Around one-half of the trial patients were given a 40-minute treatment protocol for ten consecutive days with Next Wave . With a mean increase of 24 per cent, Next Wave-treated patients showed significantly better improvements in stimulation of their total visual field compared with patients in the control group, which did not receive Next Wave stimulation. All patients had vision impairment lasting at least six months prior to the trial and had exhausted all standard therapeutic options to improve their vision.
Next Wave technology enables a revitalisation of selective communication paths between neurological cells, which may have been lost due to brain injury caused by trauma, stroke or tumour resection. The non-invasive therapy using patented Next Wave technology is clinically validated to restore vision impairment by 20 to 30 percent after brain dysfunction. In addition, glaucoma patients have shown to benefit from Next Wave.
The company plans to expand the scientific evidence for the efficacy of the Next Wave approach, particularly in stroke patients, in an expanded trial that will commence imminently. Next Wave is approved for sale in Europe, but not approved for sale or investigational use in the US.